Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 22;26(11):107970.
doi: 10.1016/j.isci.2023.107970. eCollection 2023 Nov 17.

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Shobana Anpalakhan  1 , Alessio Signori  2 , Alessio Cortellini  3   4 , Elena Verzoni  5 , Raffaele Giusti  6 , Giuseppe Aprile  7 , Paola Ermacora  8 , Annamaria Catino  9 , Stefania Pipitone  10 , Marilena Di Napoli  11 , Vieri Scotti  12 , Francesca Mazzoni  13 , Pamela F Guglielmini  14 , Antonello Veccia  15 , Marco Maruzzo  16 , Giovanni Schinzari  17 , Chiara Casadei  18 , Francesco Grossi  19 , Mimma Rizzo  20   21 , Vincenzo Montesarchio  22 , Francesco Verderame  23 , Manlio Mencoboni  24 , Fable Zustovich  25 , Lucia Fratino  26 , Caterina Accettura  27 , Saverio Cinieri  28 , Carlo Alberto Tondini  29 , Andrea Camerini  30 , Maria Chiara Banzi  31 , Mariella Sorarù  32 , Paolo Andrea Zucali  33   34 , Francesca Vignani  35   36 , Serena Ricciardi  37 , Antonio Russo  38 , Agnese Cosenza  39 , Massimo Di Maio  35   36 , Ugo De Giorgi  18 , Sandro Pignata  11 , Diana Giannarelli  40 , Carmine Pinto  31 , Sebastiano Buti  39   41 , Giuseppe Fornarini  42 , Sara Elena Rebuzzi  43   44 , Pasquale Rescigno  45 , Alfredo Addeo  46 , Giuseppe L Banna  1   47 , Melissa Bersanelli  39   48
Affiliations

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Shobana Anpalakhan et al. iScience. .

Abstract

The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been reported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma. This analysis of the INVIDIa-2 study on influenza vaccination in patients with cancer treated with immune checkpoint inhibitors (ICIs) assessed NLR and SII on overall survival (OS) by literature-reported (LR), receiver operating characteristic curve (ROC)-derived (ROC) cutoffs or as continuous variable (CV). NLR and SII with ROC cutoffs of <3.4 (p < 0.001) and <831 (p < 0.001) were independent factors for OS in multivariate analysis. SII with LR, ROC, or CV significantly predicted OS in NSCLC (p = 0.002, p = 0.003, p = 0.003), RCC (p = 0.034, p = 0.014, p = 0.014), and melanoma (p = 0.038, p = 0.022, p = 0.019). NLR with LR and ROC cutoffs predicted OS in first line (p < 0.001 for both) and second line or beyond (p = 0.006 for both); likewise SII (p < 0.001; p = 0.002 and p < 0.001). NLR and SII are prognosticators in NSCLC, RCC, and melanoma treated with ICIs.

Keywords: Immune response; Immunity; Immunology.

PubMed Disclaimer

Conflict of interest statement

The Federation of Italian Cooperative Oncology Groups (FICOG) received funding for the present study from Roche S.p.A. and Seqirus, and outside the present research from AstraZeneca, Bristol-Myers Squibb (BMS), and Sanofi. G.L.B. received fees for speaker bureau from AstraZeneca and Astellas Pharma. M.B. received funding for the present study from Roche S.p.A. and Seqirus (through FICOG as Institution, no personal fees). She also received, outside the current work, research funding from Pfizer and Novartis (through Institutions); honoraria as a speaker at scientific events (personal fees) by BMS, MSD, IPSEN, Novartis, AstraZeneca, Pierre Fabre, and Pfizer; as a consultant for advisory role (personal fees) from IPSEN, Novartis, Sanofi, Pierre-Fabre, and Merck; and personal fees for copyright transfer from Sciclone Pharmaceuticals, Pierre-Fabre, MSD, IPSEN, Pfizer, and Sanofi. S.B. received honoraria as a speaker at scientific events and in advisory role by BMS, Pfizer; MSD, Ipsen, Roche S.p.A., Eli-Lilly, AstraZeneca, and Novartis; he also received research funding from Novartis. A.C. received speaker fees and grant consultancies by AstraZeneca, MSD, IQVIA, OncoC4, and EISAI. U.D.G. has served as a consultant for Astellas, Bayer, BMS, Ipsen, Janssen, Novartis, Pfizer, Sanofi, and Pharmamar; he received research funding from AstraZeneca, Roche, and Sanofi; and received travel funds from BMS, Ipsen, Janssen, Pfizer, and Roche during the conduct of the study. P.E. received honoraria for advisory role from MSD, BMS, and Astellas. F.G. received honoraria for advisory role from Eli Lilly, Roche, Boehringer Ingelheim, AstraZeneca, Pierre Fabre, BMS, MSD, Novartis, Merck, Otsuka, Novartis, Takeda, and Bayer; seminar/talks to industry from Eli Lilly, Roche, Boehringer Ingelheim, AstraZeneca, Pierre Fabre, AMGEN, Celgene, BMS, and MSD; and research funding from AstraZeneca, BMS, and MSD. M.D.M. reports personal fees from AstraZeneca, Boehringer Ingelheim, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda; has been local principal investigator for trials sponsored by Beigene, Exelixis, Merck Sharp & Dohme, and Pfizer; and received research grant, institutional and financial support, and drug supply for the Meet-URO12 trial from Tesaro GlaxoSmithKline. D.G. received honoraria from Amgen for speaker bureau. M.M. received honoraria for advisory role from MSD and travel and accommodation expenses from Janssen, Roche, and Pfizer. C.P. received honraria for advisory role, speaker bureau, and travel and accommodation expenses from Amgen, Astellas, AstraZeneca, Bayer, Bristol Meyer Squibb, Celgene, Clovis Oncology, Eisai, Ipsen, Janssen, Incyte, Merck-Serono, Merck Sharp & Dohme, Novartis, Roche, Sandoz, Sanofi, and Servier. P.R. received honoraria for advisory role from AstraZeneca, Janssen, Gilead, BMS, and MSD Italy. M.R. received honoraria for advisory role or speaker bureau from Pfizer, Novartis, MSD, AstraZeneca, Bristol-Myers Squibb (BMS), and Merck. V.S. participated, with personal fees, in advisory boards and speaker’s bureaus for Roche S.p.A. S.C. declared his role in an international board for Eli Lilly international. M.S. received honoraria for advisory role from Janssen and grants for participation at scientific events from BMS, Ipsen, Janssen, Astella, Sanofi, Pfizer, and Novartis. E.V. received honoraria for advisory role from MSD, AstraZeneca, Ipsen, and Janssen. P.A.Z. acts in a consultant or advisory role for Sanofi, BMS, Pfizer, MSD, Astellas, Janssen, Ipsen, and Novartis, all outside the scope of work. A.A. undertook consulting or advisory roles from BMS, AstraZeneca, Boehringer Ingelheim, Roche, MSD, Pfizer, Eli Lilly, and Astellas and participated in speaker’s bureaus from Eli Lilly and AstraZeneca. All other authors declare no competing interests.

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. Zer A., Sung M.R., Walia P., Khoja L., Maganti M., Labbe C., Shepherd F.A., Bradbury P.A., Feld R., Liu G., et al. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. Clin. Lung Cancer. 2018;19:426–434.e1. - PubMed
    1. Suh K.J., Kim S.H., Kim Y.J., Kim M., Keam B., Kim T.M., Kim D.-W., Heo D.S., Lee J.S. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol. Immunother. 2018;67:459–470. - PMC - PubMed
    1. Takeda T., Takeuchi M., Saitoh M., Takeda S. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer. Thorac. Cancer. 2018;9:1291–1299. - PMC - PubMed
    1. Huang W., Luo J., Wen J., Jiang M. The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review. Front. Surg. 2022;9 - PMC - PubMed
    1. Rebuzzi S.E., Prelaj A., Friedlaender A., Cortellini A., Addeo A., Genova C., Naqash A.R., Auclin E., Mezquita L., Banna G.L. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Crit. Rev. Oncol. Hematol. 2022;179 - PubMed

LinkOut - more resources